ITM-11 boosts survival in neuroendocrine tumour trial
A new targeted radiotherapy offers hope for patients with rare neuroendocrine tumours, demonstrating a significant improvement in progression-free survival in a key clinical trial.
List view / Grid view
A new targeted radiotherapy offers hope for patients with rare neuroendocrine tumours, demonstrating a significant improvement in progression-free survival in a key clinical trial.
NETs require epidermal growth factor to grow, meaning that inhibiting EGF receptors could treat these types of tumours.
Pre-clinical research has found that CAR T cells can suppress gastrointestinal cancer cells without causing harm to healthy tissues.